Contact Us
Drug Search Results
More Filters [+]

Indisulam

Alternative Names: indisulam, e7070
Latest Update: 2024-04-19
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: CDK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eisai
Company Location: BUNKYO-KU TOKOYO 112 M0
Company CEO: Haruo Naito
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Indisulam

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Breast Cancer|Colorectal Cancer|Melanoma|Adenocarcinoma|Preleukemia|Renal Cell Carcinoma|Gastrointestinal Cancer|Myelodysplastic Syndrome

Phase 1: Oncology Solid Tumor Unspecified|Pancreatic Cancer|Lung Cancer|Gastrointestinal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCI-2012-02065

P2

Completed

Myelodysplastic Syndrome|Preleukemia

2017-06-07

E7070-A001-106

P1

Completed

Gastrointestinal Cancer|Pancreatic Cancer|Lung Cancer

2013-03-01

39%
E7070-J081-217

P2

Terminated

Gastrointestinal Cancer

2006-07-01

2004-002597-33

P2

Completed

Colorectal Cancer

2006-01-10

Recent News Events

Date

Type

Title

04/19/2024

PubMed

 Native mass spectrometry of complexes formed by molecular glues reveals stoichiometric rearrangement of E3 ligases.

04/09/2024

PubMed

 Indisulam synergizes with melphalan to inhibit Multiple Myeloma malignancy via targeting TOP2A.

03/25/2024

PubMed

 RBM39 degrader invigorates natural killer cells to eradicate neuroblastoma despite cancer cell plasticity.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions